Skip to main content
Premium Trial:

Request an Annual Quote

New Products: easyDNA's Prenatal Paternity Test

Premium

International DNA testing provider easyDNA last week launched its prenatal paternity testing service in Australia.

The test relies on a 317,000-marker SNP microarray developed by Redwood City, Calif.-based Gene Security Network. It analyzes cell-free fetal DNA collected from the maternal bloodstream. The company said that the test can be performed at nine weeks of pregnancy and is "greater than 99.9 percent accurate."

Kent, UK-based easyDNA has already launched the test in a number of other countries, including the US. The firm opened offices in Brisbane and Sydney in 2007. The new prenatal paternity service is being offered at a price of A$1,690 ($1,648).

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.